A recent exploratory analysis of survival data from clinical trials with BRAF/MEK inhibitors and ICIs in patients with metastatic melanoma [78] demonstrated a superiority of BRAF/MEK inhibitors within the first 12 months, later changing to a superiority of anti-PD-1 alone or in combination with anti-CTLA-4 with 3-year OS rates of 41% for BRAF/MEK inhibitors, 50% for anti-PD-1 alone, and 58% for anti-PD-1 plus anti-CTLA-4. This evidence concerns the gene PDCD1 and metastatic melanoma.